Johnson & Johnson postponing delivery of Janssen vaccine in Europe

The American pharmaceutical company Johnson & Johnson, the parent company of coronavaccine producer Janssen, is postponing the roll-out of that vaccine in Europe. The company does this as a precautionary measure because of reports of a possible side effect.

The pharmaceutical company says in a statement that the decision was taken together with the European health authorities. โ€œWe are aware of an extremely rare condition in which a small number of people received blood clots in combination with a reduced platelet count after the administration of our covid-19 vaccine.โ€

In the US, six women between 18 and 48 years of age received the rare form of thrombosis after being vaccinated with the vaccine. Thats why a study was started there for possible side effects. 6.8 million doses of the vaccine have been put in the US. On the advice of the CDC, the American counterpart of the RIVM, and drug watchdog FDA, a break has now been made there for the use of the vaccine.

The European Medicines Agency (EMA) is also investigating rare thrombosed reports after vaccination with Janssen in the USA.

Deliveries in Netherlands

Yesterday the first Janssen vaccines were delivered in the Netherlands. It concerns 79,200 doses. About 90,000 vaccines would be delivered later this month. In April, May and June, a total of 3 million doses of Janssen would be available in the Netherlands. It is still unclear whether these deliveries are affected by this decision. What happens with the vaccines now supplied is also unclear. The vaccines are probably not being used now, says a spokesman for Janssen.

Previously, pricking with AstraZeneca was temporarily stopped because there were reports of the rare combination of thrombosis with reduced platelet counts. The European Medicines Agency EMA investigated it and concluded that the rare clinical picture is an adverse reaction to the Astrazeneca vaccine. However, according to the EEA, the benefits of the vaccine outweigh the risks.

In the Netherlands it was then decided not to vaccinate people under the age of 60 with AstraZeneca.